Bifogade filer
Devyser launches updated Y-Chromosomal microdeletion test
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Devyser is proud to announce that its Y-chromosomal microdeletion test, Devyser AZF Extension, has been updated in accordance with the latest 2023 guidelines set by the European Molecular Genetics Quality Network (EMQN). This update makes Devyser AZF Extension the first test of its kind on the market to align with the newest EMQN standards, reinforcing our commitment to providing the most reliable and up-to-date genetic testing solutions.
“This update shows our ability to quickly update our products to meet the latest guidelines and requirements from the market. I am proud of the team that has made this update in a record pace”, says the Devyser CSO Michael Uhlin.
“Since the EMQN update in 2023, we have extensively collaborated with our customers to develop the new version and we are grateful to all that took part in the evaluation.”
The new version of the test, Devyser AZF Extension v2, will be available in mid-June as a Research Use Only (RUO) product.
About male infertility
Infertility affects 8–12% of couples worldwide and a male factor contributes to nearly 50% of couples infertility1. Azoospermia factor (AZF) deletions of the Y chromosome are the second most recurrent genetic cause of male infertility.2 Studies indicate an increased prevalence of male infertility due to a combination of older parents and pollution, with an increase in prevalence of male infertility of 76.9% between 1990 and 2019. 3
- Male infertility. Vij S.et al. Lancet, 2021
- EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomalmicrodeletions: State of the art 2023, Krausz et al, Andrology, 2023
- Global, regional and national burden of male infertility in 204 countries and territories between 1990 and 2019: an analysis of global burden of disease study, Huang B. et al, BMC Public Health, 2023